UNSPSC 51141538: Donepezil

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C24H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8SSC91326P, chemically known as 1h-inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)- but generally known as donepezil, which bears US NIH Compound Identifier 3152. European Medicines Agency schedules Donepezil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06362MIG.

UNSPSC 51141538 Donepezil, a Commodity code, nominally covers a single active pharmaceutical ingredient (donepezil hydrochloride), but recent state and local procurement activity under this code shows minimal relevant sourcing. The three most recent opportunities posted against the code address naloxone and drug deactivation systems, a direct-to-manufacturer prescription program inquiry, and generic multi-source pharmaceuticals and OTC products — none of which align with donepezil procurement. State and local issuers tagging activity to this code are attempting to source much broader pharmaceutical categories: community health departments acquiring emergency-response medications, state health agencies exploring alternative pharmaceutical distribution channels, and cooperative purchasing alliances establishing framework contracts for generic pharmaceuticals across multiple jurisdictions.

The geographic spread spans Florida (Seminole County), Texas (Health and Human Services Commission), and Minnesota (MMCAP, serving multiple states including Oregon). Issuing bodies include county health departments, state health commissions, and interstate cooperative purchasing organizations. The most recent representative opportunities are Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs; and MMCAP's S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing framework contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities. The code shows no focused donepezil-specific demand signals and little evidence of active market development for this ingredient alone under its assigned classification.